• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

    2/14/24 4:50:48 PM ET
    $VRAY
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VRAY alert in real time by email
    SC 13G/A 1 VRAY13GA32023.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 5)* ViewRay, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92672L107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 92672L107 13G Page 2 of 8 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Investments, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 0* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 0* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.00%** 12. TYPE OF REPORTING PERSON (see instructions) IA CUSIP No. 92672L107 13G Page 3 of 8 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Efrem Kamen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 0* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 0* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.00%** 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 03837C106 13G Page 4 of 8 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 0* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 0* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.00%** 12. TYPE OF REPORTING PERSON (see instructions) OO CUSIP No. 92672L107 13G Page 5 of 8 Pages Item 1. (a) Name of Issuer ViewRay, Inc. (b) Address of Issuers Principal Executive Offices 2 Thermo Fisher Way, Oakwood Village, OH, 44146 Item 2. (a) Name of Person Filing Pura Vida Investments, LLC Pura Vida Master Fund, Ltd. Efrem Kamen (collectively, the "Reporting Persons"). (b) The address of the principal place of the Reporting Persons is located at: Pura Vida Investments, LLC 545 West 25th Street, 19th Floor New York, New York 10001 (c) For citizenship of Reporting Persons, see Item 4 of the cover sheet for each Filer. (d) Title of Class of Securities Common Stock (e) CUSIP Number 92672L107 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1) (ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1) (ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). CUSIP No. 92672L107 13G Page 6 of 8 Pages Item 4. Ownership. (a) Amount beneficially owned: Pura Vida Investments LLC 0* shares Efrem Kamen 0* shares Pura Vida Master Fund, Ltd. 0* shares (b) Percent of class: Pura Vida Investments LLC 0.00%** Efrem Kamen 0.00%** Pura Vida Master Fund, Ltd. 0.00%** (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: Pura Vida Investments LLC 0* shares Efrem Kamen 0* shares Pura Vida Master Fund, Ltd. 0* shares (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: Pura Vida Investments, LLC 0* shares Efrem Kamen 0* shares Pura Vida Master Fund, Ltd. 0* shares *Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. Efrem Kamen serves as the managing member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Pura Vida Master Fund and the Managed Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section CUSIP No. 92672L107 13G Page 7 of 8 Pages 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein, if any. **The percentages herein are calculated based upon 0 shares of Common Stock of the Issuer outstanding per the Issuers Form 25, filed with the Securities and Exchange Commission, delisting their securities from the NASDAQ exchange on September 8, 2023. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2024[CB1] CUSIP No. 92672L107 13G Page 8 of 9 Pages Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member CUSIP No. 92672L107 13G Page 9 of 9 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of any issuer until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. For that purpose, the undersigned hereby constitute and appoint Pura Vida Investments, LLC, a limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases and sales, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Dated: February 14, 2024 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member [CB1]Should be under header on next page?
    Get the next $VRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRAY

    DatePrice TargetRatingAnalyst
    5/11/2023$4.00 → $1.00Buy → Neutral
    B. Riley Securities
    4/17/2023$7.00 → $1.25Buy → Hold
    Jefferies
    4/14/2023Outperform → Perform
    Oppenheimer
    4/14/2023Buy → Neutral
    BTIG Research
    4/14/2023$7.00 → $1.75Buy → Hold
    Stifel
    1/25/2022$7.00Buy
    Stifel
    1/11/2022$7.00Neutral → Buy
    B. Riley Securities
    10/14/2021$7.00Neutral
    B. Riley Securities
    More analyst ratings

    $VRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Shah Sanket

      4 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:05:01 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Podbelski Adam Andrew

      4 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:04:48 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3: New insider Shah Sanket claimed ownership of 66,659 shares

      3 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:03:11 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ViewRay downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded ViewRay from Buy to Neutral and set a new price target of $1.00 from $4.00 previously

      5/11/23 6:49:02 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay downgraded by Jefferies with a new price target

      Jefferies downgraded ViewRay from Buy to Hold and set a new price target of $1.25 from $7.00 previously

      4/17/23 7:40:30 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay downgraded by Oppenheimer

      Oppenheimer downgraded ViewRay from Outperform to Perform

      4/14/23 8:06:57 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Financials

    Live finance-specific insights

    See more
    • ViewRay Announces First Quarter 2023 Results

      DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.Received 13 new orders for MRIdian systems, totaling $68.3 million.Total backlog increased to $411.0 million as of March 31, 2023, compared to approximately $331.0 million as of March 31, 2022.Cash and cash equivalents, inclusive of restricted cash, was $85.5 million as of March 31, 2023.Net l

      5/10/23 4:01:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023

      DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars." About ViewRay® ViewRay, Inc. (NASDAQ:VRA

      5/9/23 4:10:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023

      DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars". About ViewRay® ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MR

      4/12/23 5:25:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/14/24 4:50:48 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/12/24 6:26:25 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/7/24 6:13:01 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUBURU Appoints Brian Knaley as new CEO

      NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental

      11/1/23 4:30:00 PM ET
      $BURU
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Miscellaneous
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets

      DENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (NASDAQ:VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. Trading of the Company's common st

      7/21/23 4:01:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay® Files Voluntary Chapter 11 Petitions

      Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 pro

      7/17/23 7:00:00 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ViewRay Inc.

      25-NSE - ViewRay, Inc. (0001597313) (Subject)

      9/8/23 10:12:09 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ViewRay, Inc. (0001597313) (Filer)

      9/7/23 5:28:43 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by ViewRay Inc.

      NT 10-Q - ViewRay, Inc. (0001597313) (Filer)

      8/14/23 4:03:14 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • NUBURU Appoints Brian Knaley as new CEO

      NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental

      11/1/23 4:30:00 PM ET
      $BURU
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Miscellaneous
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

      DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

      1/9/23 6:00:00 AM ET
      $AXGN
      $MIRO
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NUBURU Names Brian Knaley as Chief Financial Officer

      Three-time public company CFO joins NUBURU with deep experience in leading business transformation and optimization of financial processes on a global scale NUBURU®, the industry leader in high power and high brightness industrial blue lasers, today announced that it has appointed Brian Knaley as Chief Financial Officer. In this strategic role, Mr. Knaley will oversee all aspects of finance and investor relations as NUBURU accelerates and implements its growth strategy to expand the presence of its blue laser technology across target markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005131/en/Three-time public compan

      3/22/22 9:00:00 AM ET
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care